• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The TORCH trial: Combination of salmeterol and fluticasone in treating COPD [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
July 6, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The combination of salmeterol and fluticasone did not significantly reduce all-cause mortality in patients with chronic pulmonary obstructive disease (COPD)

2. When compared with salmeterol alone, fluticasone alone, and placebo, combination therapy significantly reduced the risk of exacerbations and the need for systemic corticosteroids during exacerbations

Original Date of Publication: February 22, 2007

Study Rundown: The Towards a Revolution in COPD Health (TORCH) trial explored whether combination therapy with salmeterol (a long-acting beta-agonist) and fluticasone proprionate (an inhaled corticosteroid) would significantly reduce mortality in patients with COPD as compared with placebo. This landmark study determined that combination therapy did not significantly reduce all-cause mortality when compared with placebo (HR 0.825; 95%CI 0.681-1.002). Treatment with combination therapy, however, did significantly reduce the risk of moderate or severe COPD exacerbations (HR 0.75; 95%CI 0.69-0.81), while also reducing the likelihood that patients would require systemic corticosteroids during their exacerbations when compared with placebo (HR 0.57; 95%CI 0.51-0.64).

In summary, treating patients with COPD with combination therapy including a long-acting beta-agonist and inhaled corticosteroid did not significantly reduce mortality when compared with placebo. This combination therapy, however, does significantly reduce the risk of exacerbation and the risk of requiring systemic corticosteroids for exacerbation treatment.

Click to read the study in NEJM

In-Depth [randomized, controlled study]: Originally published in 2007 in NEJM, this study randomized 6,184 COPD patients to 4 different treatment arms: 1) 1,545 were randomized to the placebo group, 2) 1,542 were randomized to the salmeterol-only group, 3) 1,551 were randomized to the fluticasone-only group, and 4) 1,546 were randomized to the combination therapy group (i.e., salmeterol and fluticasone). Eligible patients had at least a 10 pack-year smoking history, were between 40-80 years old, diagnosed with COPD, exhibited a pre-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 60% of the predicted value, showed an increase in FEV1 with use of 400 mcg of albuterol of less than 10% of the predicted value, and had a ratio of pre-bronchodilator FEV1 to forced vital capacity (FVC) of equal to or less than 0.70. Patients were excluded if they had a non-COPD pulmonary condition (e.g., lung cancer, sarcoidosis, asthma), prior lung volume reduction surgery or lung transplant, long term supplemental oxygen (i.e., greater than or equal to 12 hours/day), less than 6 weeks of oral corticosteroids, serious uncontrolled disease, received any investigational drugs in the 4 weeks prior to entry, evidence of alcohol or drug abuse, known hypersensitivity to inhaled corticosteroids, bronchodilators, or lactose, or known deficiency of alpha-1 anti-trypsin.

RELATED REPORTS

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

2 Minute Medicine Rewind January 23, 2023

Racial differences exist in emphysema prevalence in adults with normal spirometry findings

There was no significant difference in all-cause mortality between patients in the combination therapy group compared to the placebo group (HR 0.825; 95%CI 0.681-1.002). While there was no significant difference in all-cause mortality when comparing combination therapy with salmeterol-only therapy (HR 0.932, 95%CI 0.765-1.134), combination therapy did significantly reduce all-cause mortality when compared with fluticasone alone (HR 0.774; 95%CI 0.641-0.934). Combination therapy did significantly reduce the risk of moderate or severe exacerbation as compared with salmeterol-only (HR 0.88; 95%CI 0.81-0.95), fluticasone-only (HR 0.91; 95%CI 0.84-0.99), and placebo (HR 0.75; 95%CI 0.69-0.81). Moreover, combination therapy significantly reduced the risk of exacerbations requiring systemic corticosteroids compared to salmeterol-only (HR 0.71; 95%CI 0.63-0.79), fluticasone-only (HR 0.87; 95%CI 0.78-0.98), and placebo (HR 0.57; 95%CI 0.51-0.64).

Image: PD

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: copdemphysema
Previous Post

Unhealthy food cues prominent in children’s programming in the UK and Ireland

Next Post

Hypertension and use of β-blockers linked to increased risk of psoriasis

RelatedReports

2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
Non-invasive ventilation linked with lower mortality in COPD exacerbations
Chronic Disease

Racial differences exist in emphysema prevalence in adults with normal spirometry findings

August 10, 2022
Novel combination therapy may be effective for noncirrhotic HCV infection [UNITY-1 trial]
Chronic Disease

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

June 29, 2022
Next Post
Study shows poor follow up of children with high blood pressure

Hypertension and use of β-blockers linked to increased risk of psoriasis

Mortality risk associated with low-birth weight

Home self-sonograms for assisted reproduction comparable to in-office imaging

Increased risk of hookah use in urban and high socioeconomic adolescents

Increased risk of hookah use in urban and high socioeconomic adolescents

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options